Drug Profile
Chimeric antigen receptor T-cell therapy - Biostax/Super-T Cell Cancer Company
Alternative Names: Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy; Super CAR-T Cocktail therapyLatest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator Immune Therapeutics; Super T Cell Cancer Company
- Developer Biostax
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2019 No recent reports of development identified for clinical-Phase-Unknown development in Cancer in China (Parenteral)
- 21 Apr 2016 Immune Therapeutics in-licenses Chinese Chimeric Super Antigen T cell (CAR-T) cocktail therapy from Super-T Cell Cancer Company
- 21 Apr 2016 Clinical trials in Cancer in China (Parenteral) before April 2016